Comparative Efficacy, Safety and Pharmacokinetics of Verapamil SR vs Verapamil IR in Hypertensive Patients Nery T. FuenmayorBarbara M. FagginLuigi X. Cubeddu OriginalPaper 27 October 2012 Pages: 1 - 11
Use of Ambulatory Blood Pressure Monitoring in the Management of Antihypertensive Therapy Jean-Michel MallionAnne MaitreFrederic Tremel OriginalPaper 27 October 2012 Pages: 12 - 16
Ambulatory Blood Pressure Monitoring G. ManciaS. OmboniA. Villani OriginalPaper 27 October 2012 Pages: 17 - 22
Calcium Overload — An Important Cellular Mechanism in Hypertension and Arteriosclerosis G. Fleckenstein-GrünM. FreyA. Fleckenstein OriginalPaper 27 October 2012 Pages: 23 - 30
Secondary Prevention with Calcium Antagonists after Acute Myocardial Infarction Jørgen Fischer Hansen OriginalPaper 27 October 2012 Pages: 33 - 43
Cardiac Hypertrophy and Aortic Compliance after Calcium Channel Antagonism in Hypertension B. M. PannierJ. L. TualM. E. Safar OriginalPaper 27 October 2012 Pages: 44 - 47
Regional Myocardial Blood Flow and Coronary Reserve in Hypertensive Patients O. ParodiD. NegliaL. Donato OriginalPaper 27 October 2012 Pages: 48 - 55
Is Salt Restriction Necessary in Hypertensive Patients Treated with Calcium Antagonists? J. Redon OriginalPaper 27 October 2012 Pages: 61 - 65
Risk-Benefit Aspects of Antihypertensive Drugs H. HolzgreveM. Middeke OriginalPaper 27 October 2012 Pages: 67 - 73
Swiss Hypertension Treatment Programme with Verapamil and/or Enalapril in Diabetic Patients Claudia FevrierPaolo FerrariWalter F. Riesen OriginalPaper 27 October 2012 Pages: 74 - 84
The Effect of Sustained Release Verapamil on Glucose Metabolism in Patients with Non-Insulin-Dependent Diabetes Mellitus J. LyngsøeM. Busch SørensenJ. Juul Holst Short Communication 27 October 2012 Pages: 85 - 87
Effects of Treatment with Verapamil SR and Captopril on the Lipid Profile of Hypertensive Patients Maria CatalanoCarlo CislaghiArnaldo Libretti OriginalPaper 27 October 2012 Pages: 88 - 93
Sodium Intake Does Not Influence the Effect of Verapamil in Hypertensive Patients with Mild Renal Insufficiency Luis M. RuilopeMaria C. CasalJose L. Rodicio OriginalPaper 27 October 2012 Pages: 94 - 98
Is Renal Protection with Calcium Antagonists Possible? P. García-CosmesA. MortezoJ. F. Macías-Núñez OriginalPaper 27 October 2012 Pages: 99 - 102
Use of Cell Culture for Optimisation of Direct Antiatherogenic Therapy with Verapamil A. N. OrekhovE. M. PivovarovaV. V. Tertov OriginalPaper 27 October 2012 Pages: 105 - 110
Arterial Calcinosis, Chronic Renal Failure and Calcium Antagonism S. J. MarchaisA. P. GuerinG. M. London OriginalPaper 27 October 2012 Pages: 119 - 122
Can the Coronary Atherosclerotic Process Be Influenced by Calcium Antagonists? G. KoberW. SchneiderM. Kaltenbach OriginalPaper 27 October 2012 Pages: 123 - 127
Preliminary Clinical Experience with Calcium Antagonists in Atherosclerosis B. MagnaniC. Dal PalùVerapamil in Hypertension Atherosclerosis Study Investigators OriginalPaper 27 October 2012 Pages: 128 - 133
Quality of Life in the Treatment of Hypertension Astrid FletcherChristopher Bulpitt OriginalPaper 27 October 2012 Pages: 135 - 140
Does a Reduction in Left Ventricular Hypertrophy Reduce Cardiovascular Morbidity and Mortality? Franz H. MesserliFederico Soria OriginalPaper 27 October 2012 Pages: 141 - 146
Choosing the Correct Drug for the Individual Hypertensive Patient L. H. Opie OriginalPaper 27 October 2012 Pages: 147 - 155